PackGene & CMRI Announce AAV Screening Kit for Global Gene Therapy R&D
CompanyDeals

PackGene & CMRI Announce AAV Screening Kit for Global Gene Therapy R&D

Suzhou HemaCell Receives NMPA IND Approval for First‑In‑Class Megakaryocyte Injection – Thrombocytopenia Treatment
CompanyDrug

Suzhou HemaCell Receives NMPA IND Approval for First‑In‑Class Megakaryocyte Injection – Thrombocytopenia Treatment

Everest Medicines Reports 48 % YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone
Company

Everest Medicines Reports 48 % YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone

Luye Pharma Reports 1H 2025 Revenue Growth of 3.5 % Amid Oncology and CNS Gains
Company

Luye Pharma Reports 1H 2025 Revenue Growth of 3.5 % Amid Oncology and CNS Gains

Shanghai Pharma Reports 2025 Interim Results: 1.6% Revenue Rise, 41% Profit Surge
Company

Shanghai Pharma Reports 2025 Interim Results: 1.6% Revenue Rise, 41% Profit Surge

Zennova & Rapafusyn Forge BioCarier‑Powered RapaGlue Collaboration – 2025
CompanyDeals

Zennova & Rapafusyn Forge BioCarier‑Powered RapaGlue Collaboration – 2025

Boehringer Ingelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China
CompanyDrug

Boehringer Ingelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China

Innovent Biologics Revenue Soars 50% in H1 2025 – Oncology Growth Fuels GLP‑1 Expansion
Company

Innovent Biologics Revenue Soars 50% in H1 2025 – Oncology Growth Fuels GLP‑1 Expansion

NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed
Policy / Regulatory

NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed

HarbourBioMed Reports 327 % Revenue Surge, Launches HCAb‑Based Élancé Therapeutics
Company

HarbourBioMed Reports 327 % Revenue Surge, Launches HCAb‑Based Élancé Therapeutics

Santen Receives Boao Lecheng Approval for RYJUSEA – A Preservative‑Free Atropine Eye Drop for Pediatric Myopia
CompanyDrug

Santen Receives Boao Lecheng Approval for RYJUSEA – A Preservative‑Free Atropine Eye Drop for Pediatric Myopia

Anglikang Secures Exclusive Rights to Yafei’s IMD‑1005 in China
CompanyDeals

Anglikang Secures Exclusive Rights to Yafei’s IMD‑1005 in China